Fred Porter, Ph.D.
Chief of Staff and Technical Operations Officer
Fred Porter, Ph.D., serves as Chief of Staff and Technical Operations Officer at Taysha Gene Therapies. He has served as Chief of Staff since 2022 and as Technical Operations Officer since 2020.
Fred is an accomplished biopharmaceutical development and manufacturing leader with over 15 years of experience advancing novel candidates and production platforms from discovery through commercialization. Before joining Taysha, Fred served as Senior Vice President of Technical Development and Manufacturing at BridgeBio Pharma, where he led the development and industrialization of the organization’s portfolio of novel gene therapies for rare diseases. Before BridgeBio, Fred served as Senior Director of Product Development at the Duke Human Vaccine Institute, where he led product development and cGMP manufacturing for novel vaccine and therapeutic candidates to support exploratory clinical trials. Fred has also held various research and development roles at GlaxoSmithKline plc (GSK) and Novartis, where he contributed to the advancement of novel viral vaccine candidates.
Fred earned a B.S. in biochemistry from Rutgers University and an M.S. in microbiology from Seton Hall University. He earned a Ph.D. in biochemistry from the University of Wisconsin-Madison, where he also completed his post-doctoral research.
